<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04192331</url>
  </required_header>
  <id_info>
    <org_study_id>CABC012</org_study_id>
    <nct_id>NCT04192331</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer</brief_title>
  <official_title>A Single-arm Opened Randomized Phase II Study of Nab-paclitaxel Dose Schedual in Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      What is the best dosage of Nab-Paclitaxel for chinese? This study would divide patients into
      two dosage groups: 1) 125mg/m2, 30 minutes intravenous injection, d1, 8, 21 days for a
      cycle(clinical use); 2) 125mg/m2 d1, 8, 15, 30 minutes intravenous injection, 28 days for a
      cycle(guideline recommand). Treatment to disease progression. The efficacy (CR, PR, SD, PD)
      is evaluated every 2-4 cycles.If the patient withdraws from the trial because he cannot
      tolerate the toxicity caused by one of the drugs, such as neurotoxicity or bone marrow
      toxicity, it is recommended to switch to other drugs and follow up to PFS and OS.Each group
      was planned to include 30 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">February 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>PFS of two regimen</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>progession free survival and objective remission rate was put in to assessment after 2-4 cycle of treatment of either two regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effect of two regimen</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>toxicity and tolerability would be evaluated after every cycle of treatment and will report a SAE within 24h</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>2/3dose strategy</arm_group_label>
    <description>HER2 negative advanced breast cancer patient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3/4dose strategy</arm_group_label>
    <description>HER2 negative advanced breast cancer patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel regimen1</intervention_name>
    <description>nab-paclitaxel regimen1 means use abraxine with 125mg/m2 at day 1 and day 8 per 21d.</description>
    <arm_group_label>2/3dose strategy</arm_group_label>
    <other_name>regimen1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel regimen2</intervention_name>
    <description>nab-paclitaxel regimen2 means use abraxine with 125mg/m2 at day 1 and day 8 and day 15 per 28d.</description>
    <arm_group_label>3/4dose strategy</arm_group_label>
    <other_name>regimen2</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HER2 negative advanced breast cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Female, aged &gt; 18 years old and &lt; 70 years old;

          -  Histopathologically confirmed HER-2 negative (definition: immunohistochemical IHC 0,
             or 1+, or in situ hybridization ISH, defined as the ratio of HER2 gene copy number to
             CEP17 signal number less than 2.0, or for single probe detection, HER2 gene copy
             number less than 6) in patients with recurrent or metastatic breast cancer;

          -  No treatment for recurrent and metastatic diseases or up to two chemotherapy regimens
             has been received in the past;Previous treatment regimens (neoadjuvant, adjuvant or
             rescue therapy) must include any combination or other sequence of administration of
             anthracyclines (e.g. doxorubicin, epirubicin) and taxanes (e.g. paclitaxel,
             docetaxel);

          -  With measurable lesions;

          -  The physical condition score of the Eastern American Cancer Collaboration Group (ECOG)
             was less than 2;

          -  Expected survival period&gt;3 months;

        Exclusion Criteria

          -  New York Heart Association NYHA scores identify patients with congestive heart failure
             at grade II or above;Uncontrolled brain metastasis;

          -  Patients with severe systemic infection;Patients with peripheral nerve injury of
             degree II or above, or known drug allergy or intolerance within 4 weeks before
             admission;

          -  Important organ disorders or diseases: liver and kidney dysfunction, history of
             myocardial infarction, unstable heart disease, chronic active hepatitis,etc;There is a
             history of other malignant tumors within 5 years (except cured cervical cancer or skin
             basal cell carcinoma);

          -  Patients who had received other antineoplastic treatments or other experimental drugs
             within one month before treatment;

          -  Patients who also participated in other clinical trials;

          -  Researchers believe that patients are not suitable for any medical condition to enter
             the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BeijingCancerH</name>
      <address>
        <city>Haidian</city>
        <state>Beijing</state>
        <zip>10010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>huiping Li, senenior</last_name>
      <phone>+86 01088196380</phone>
      <email>huipingli2012@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 14, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Li Huiping</investigator_full_name>
    <investigator_title>Head of the department of breast oncology</investigator_title>
  </responsible_party>
  <keyword>nab-paclitaxel</keyword>
  <keyword>advanced breast cancer</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

